ABSTRACT
Objective To compare the effects of salmeterol and fluticasone propionate combined montelukastin the treatment of patients with bronchial asthma.Methods Ninety-eight bronchial asthma patients from April 2014 to March 2016 in the Fourth People's Hospital Sichuan Province were selected anddivided into observation group and control group with 49 patients in each group according to the above principles by prospective study.The control group was given salmeterol treatment,and the observation group was added given montelukast treatment based on the control group.The treatment days were 15 d recorded the prognosis of the two groups.Results The total effective rates of the observation group and the control group were 95.9％ and 81.6％ respectively,the total effective rate of the observation group was significantly higher than that of the control group (P ＜ 0.05).The FEV1 and FVC values after treatment in the observation group and control group were significantly higher than before treatment (P ＜ 0.05),while the FEV1 and FVC values in the observation group after treatment were significantly higher than those in the control group (P ＜ 0.05).The scores of ACT scale after treatment of two groups were obviously higher than before treatment,and the score of observation group was statistically higher than control group after treatment (P ＜ 0.05).During treatment,there was no statistical significance on adverse reaction between two groups.Conclusion Salmeterol and fluticasone propionate combined montelukast in the treatment of patients with bronchial asthma can promote the improvement of lung function,so as to improve the quality of life and clinical treatment.
ABSTRACT
OBJECTIVE:To observe clinical efficacy and safety of salmeterol and fluticasone propionate in the treatment of mod-erate and severe bronchial asthma. METHODS:98 patients with moderate and severe bronchial asthma were selected from our hospi-tal were included in the study and were randomly divided into control group(49 cases,3 cases withdrew from the test and 46 cases completed the test)and observation group(49 cases,2 cases withdrew from the test and 47 cases completed the test). Control group was given Budesonide aerosol preparation,1 dose,bid;observation group was given Salmeterol and fluticasone propionate inhala-tion,1 dose,bid. The treatment course lasted for 2 months. Clinical efficacy,lung function indexes,the time of clinical symptom disappearance,FEV1,PD20,ACT score,asthma attack times within half an year,EO%and ECP in serum and sputum,and the oc-currence of ADR were compared between 2 groups. RESULTS:After treatment,total effective rate of observation group was signifi-cantly higher than that of control group(95.73% vs. 76.09%);FVC,FEV1 and PEF and other indexes of 2 groups were increased significantly,and the observation group was significantly higher than the control group;the disappearance time of pulmonary rales, wheezing,dyspnea and cough in observation group were significantly shorter than in control group;PD20 and ACT score of 2 groups were significantly increased,ACT score of observation group was significantly higher than that of control group;EO% and ECP in serum and sputum of observation group were significantly lower than those of control group,there was statistical significance (P0.05). All ADRs disappeared after drug withdrawal. CONCLUSIONS:Therapeutic efficacy of salmeterol and fluticasone propio-nate is better than budesonide in the treatment of moderate and severe bronchial asthma,and can effectively improve lung function, shorten the time of clinical symptoms disapperance and reduce the level of inflammatory factor with and good safety.
ABSTRACT
Objective:To observe the effects of salmeterol and fluticasone combined with the conventional treatment on the airway remodeling and bone metabolism in the patients with severe chronic obstructive lung disease ( chronic obstructive pulmonary disease, COPD. Methods:Totally 90 patients with severe COPD were divided into the observation group and the control group according to the order of admission. The control group was received the conventional treatment, and the observation group was treated with salmeterol and fluticasone additionally. The course of treatment was 8 weeks. Before the treatment and in the 3rd and 12th month after the treat-ment, the changes in the levels of bone mineral density ( BMD) in femoral neck bone, serum osteocalcin ( BGP) , alkaline phosphatase (AKP), the total number of induced sputum cells, neutrophils percentage, forced expiratory volume in one second (FEV1), leukocyte mediated element 8 (IL-8), matrix metalloproteinase 9 (MMP-9) and other indicators were detected and compared. Results: BGP, AKP and BMD of the two groups in the 3rd month after the treatment were not significantly changed (P>0. 05), while in the 12th month after the treatment, BMD in the observation group was significantly lower than that in the control group and that before the treat-ment, and BGP and AKP in the observation group were significantly higher than those in the control group and that before the treatment (P<0. 05). The total number of induced sputum cells, the percentage of neutrophils, FEV1, MMP-P and IL-8 in the two groups were significantly improved in the 12th month after the treatment (P<0. 05), and the difference between the two groups was statistically sig-nificant except IL-8 (P<0. 05). Conclusion:Salmeterol and fluticasone propionate can effectively improve airway remodeling in the patients with COPD. Short time use of salmeterol and fluticasone propionate shows no adverse effect on the bone metabolism, while long-term use would lead to reduced bone mineral density.
ABSTRACT
OBJECTIVE:To systematically review the efficacy and safety of salmeterol and fluticasone propionate aerosol in the treatment of AECOPD and provide evidence-based reference for the clinical treatment. METHODS:CJFD,Wanfang database, VIP,CBM,Cochrane Library,PubMed and EMBase were retrieved to collect the randomized controlled trial(RCT)of efficacy and safety of salmeterol and fluticasone propionate aerosol in the treatment of AECOPD. After information collection and quality evalua-tion,Meta-analysis was performed by using Rev Man 5.1 software. RESULTS:There were totally 17 RCTs,including 2 872 pa-tients. Results of Meta-analysis showed FEV1[SMD=0.47,95%CI(0.41,0.53),P<0.001],FEV1/FVC [SMD=1.08,95%CI(0.76, 1.39),P<0.001],FEV1 percentage of predicted value[SMD=0.83,95%CI(0.60,1.06),P<0.001] and incidence of adverse reac-tions [RR=1.38,95%CI(1.02,1.87),P=0.03] in test group were significantly higher than control group,with significant differenc-es. CONCLUSIONS:Salmeterol and fluticasone propionate aerosol has good efficacy in the treatment of AECOPD,can better im-prove patients’lung function and the safety needs to be improved. Due to the limit of research methodology,it remains to be fur-ther verified by large-sample and high-quality RCT.
ABSTRACT
Objective To investigate the clinical effects of salmeterol and fluticasone propionate combined with tiotropium in treatment of chronic obstructive pulmonary disease (COPD).Methods 78 patients with COPD were randomly divided into two groups according to hospitalized order ,the control group(n=39)was given salmeterol and fluticasone propionate on the basis of the conventional treatment while the observation group ( n=39 ) was given tiotropium on the basis of the control group .The clinical efficacy and adverse events were compared between the two groups.Results After treatment,FVC,FEV1 and FEV1/FVC of the observation group were (1.90 ±0.19) L, (2.26 ±0.25)L and(68.41 ±5.65)%,which were significantly higher than those before treatment (t2 =9.92, 11.62,9.72;t1=9.70,8.76,9.41,all P0.05 ). Conclusion Salmeterol and fluticasone propionate combination of tiotropium in the treatment of COPD has significant effect,and it can effectively alleviate clinical symptoms and improve lung function ,so it is safe and reliable,which should be widely applied in clinical .